ARTICLE | Company News
ChemoCentryx, GlaxoSmithKline deal
January 18, 2010 8:00 AM UTC
GlaxoSmithKline exercised its option to license exclusive, worldwide rights to develop and commercialize Traficet-EN ( CCX282-B) and two back-up compounds from ChemoCentryx. Traficet-EN, a CC chemok...